Piper Jaffray, Mizuho Initiate Coverage of CareDx with Bullish Outlooks | GenomeWeb

NEW YORK (GenomeWeb) – Piper Jaffray and Mizuho Securities today initiated coverage of transplant molecular diagnostics firm CareDx with bullish views of the company's stock and market opportunities for its tests.

Piper Jaffray's William Quirk put an Overweight rating and a $13 share price target on CareDx's shares, while Mizuho's Peter Lawson rated the company's stock at Buy and gave it a $15 price target.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.